Gamma Knife Stereotactic Radiosurgery for the Treatment of Primary and Metastatic Ocular Malignancies

Arnett, A.L.H.; Reynolds, Margaret; Pulido, José S.; Parney, Ian F.; Laack, Nadia N.

doi:10.1159/000478271

Cited by 14 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arnett et al's study [36] had the following findings; median age at diagnosis was 70 years and median follow-up was 26.4 months. Primary ocular melanoma was diagnosed in 17 (61%) patients (stage T2a-T4e).…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Uveal melanoma survival rates after single dose stereotactic radiosurgery

Furdová¹,

Babál²,

Kobzová³

et al. 2018

neo

View full text Add to dashboard Cite

This paper presents the long-term results of single dose stereotactic radiosurgery for intraocular uveal malignant melanoma, and summarizes the results of the retrospective study in 170 Slovak patients. A group of uveal melanoma patients (149 choroidal melanoma, 21 ciliary body melanoma) from 20 to 92 years of age with 59 year median were treated in 2001-2016. There were 81males (47.7%) and 89 females 89 (52.3%). The median overall follow-up time was three years. The median tumor volume at baseline was 0.5 cm3 (ranging from 0.2 to 1.6 cm3). The therapeutic dose was 35.0 Gy by 99% of dose volume histogram. The survival after single dose stereotactic radiosurgery was 96% in one year, 93% in two years, 84% in five years, 80% in seven years and 52% in eleven years. Secondary enucleation was necessary for 22 patients because of secondary glaucoma complication. The enucleation free interval ranged from one to six years. The survival rates in five year intervals and necessity of secondary enucleation due to complications after single dose stereotactic radiosurgery is comparable to other techniques.

show abstract

Section: Discussionmentioning

confidence: 92%

“…The mean dose to the optic nerve was 12.6 Gy. The 5-year survival for subjects presenting with primary ocular melanoma lesions was 90% and only 1 patient required enucleation after radiation treatment [36].…”

Section: Discussionmentioning

confidence: 97%

Uveal melanoma survival rates after single dose stereotactic radiosurgery

Furdová¹,

Babál²,

Kobzová³

et al. 2018

neo

View full text Add to dashboard Cite

show abstract

“…Late examinations recommend that gamma knife radiosurgery and SRS may be an appropriate choice for the treatment of uveal melanoma in those patients in whom ulcers are not suitable for conventional brachytherapy. The findings in the setting recommend a part of SRS in the treatment of selected cases of uveal melanoma [24].…”

Section: Discussionmentioning

confidence: 81%

Uveal Melanoma

Horkovičová¹,

Furdová²

2021

Melanoma

View full text Add to dashboard Cite

Currently, melanoma of uvea is the most well-known essential tumor, which is intaocular and malignant. Treatment using radiation has now supplanted enucleation as the therapy of decision. Radioactive eye plaques and treatment using proton are being the two most examined radiotherapeutic modalities. All the more as of late, stereotactic radiosurgery and fractionated stereotactic radiotherapy have risen as promising, non-intrusive medicines for uveal melanoma. Technique called stereotactic radiosurgery might be viewed as like „not surgery” on the grounds no extractions are included. All things being equal, it is a serious strategy for radiation treatment that conveys high dosages of radiation to exceptionally little territories and volumes.

show abstract

“…In the setting of choroidal malignancies, therapeutic implementation can involve the use of external beam radiotherapy, 19 brachytherapy, 19 gamma knife radiosurgery, 20 proton beam radiotherapy, 21 plaque radiotherapy, 22 transpupillary thermotherapy, 23 photodynamic therapy, 24 intravitreal anti-vascular endothelial growth factor injection, 25 systemic chemotherapy, 26 immunotherapy, 26 and/or hormone therapy. 27 The strategic employment of these modalities depends on various factors including histological subtype, laterality, number of choroidal tumors, systemic status, and characterization of metastatic propensity.…”

Section: Therapymentioning

confidence: 99%

Impact of Therapy & Age in Choroidal Cancers: A Retrospective Cohort Analysis of 7722 Patients from a US National Database

Hussain¹,

Khan²,

Ali³

2021

OPTH

View full text Add to dashboard Cite

Background Collectively, choroidal cancers represent a vast array of histopathologically diverse constituencies with profound repercussions related to mortality and metastasis. Prognosticated factors provide utility in determining clinical management and outcome propensities. To date, measures to collectively characterize choroidal cancers as a class are not impressive. This study aims to shed light on the affiliation of age and therapeutic modalities to survival in patients diagnosed with choroidal cancers. Methods Cohort analysis using the Surveillance, Epidemiology, and End Results (SEER) program, a freely accessible population-based database, was executed from 1975 to 2016, a 41-year time window. Univariable and multivariable Cox regression assessed survival with age and various therapeutic modalities as primary independent variables. Adjustment for several demographical and clinical variables was performed. Results This cohort consisted of 7722 patients at the time of diagnosis. Multivariable Cox regression demonstrated increased cause-specific hazards of 71.8% for patients aged 75+ years (HR = 1.718, CI 1.155–2.555, p < 0.008) as compared to patients aged 0–24 years. 16.2% and 58.0% increases in cause-specific mortality were showcased in patients diagnosed with 8770/3: mixed epithelioid and spindle cell melanoma (HR = 1.16, p = 0.029) and 8771/3: epithelioid cell melanoma of the choroid (HR = 1.580, p < 0.001) compared to individuals diagnosed with 8720/3: malignant melanoma NOS of the choroid. Chemotherapy significantly influenced survival in patients with choroidal cancers compared to those who did not receive chemotherapy or had an unknown status (HR = 0.377, CI 0.292–0.486, p < 0.001). Conclusion Like most cancers, choroidal cancers showcase poor clinical trajectory with advanced age. Specific ICD-O-3 histological subtypes predispose to increased mortality. Therapeutic modalities such as radioactive implants and chemotherapeutic agents demonstrate decreased cause-specific mortality compared to alternative treatments. Altogether, nuanced influences of age and therapy are revealed when evaluating choroidal cancers as a class, irrespective of subtype.

show abstract

Gamma Knife Stereotactic Radiosurgery for the Treatment of Primary and Metastatic Ocular Malignancies

Cited by 14 publications

References 17 publications

Uveal melanoma survival rates after single dose stereotactic radiosurgery

Uveal melanoma survival rates after single dose stereotactic radiosurgery

Uveal Melanoma

Impact of Therapy & Age in Choroidal Cancers: A Retrospective Cohort Analysis of 7722 Patients from a US National Database

Contact Info

Product

Resources

About